Wipfli Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Wipfli Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$745K	Buy	+2,572	New	+$740K	0.05%	161

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wipfli Financial Advisors's VRTX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2022: 2,572 shares worth $745K. The stake represents 0.05% of the portfolio and ranks #161 among its holdings.

1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

Wipfli Financial Advisors held 2,572 shares of Vertex Pharmaceuticals worth $745K as of Q3 2022.
Vertex Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
Vertex Pharmaceuticals made up 0.05% of Wipfli Financial Advisors's portfolio in Q3 2022, its #161 holding.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.